{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:01:28Z","timestamp":1790521288120,"version":"4.1.0"},"reference-count":43,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0420-0","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T09:45:52Z","timestamp":1540201552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":160,"title":["Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study"],"prefix":"10.1136","volume":"6","author":[{"given":"Asim","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R","family":"Plimack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S","family":"Ernstoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel D","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Carducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y C","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Spratlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmer","family":"Berghorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J","family":"Hammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"issue":"7","key":"420_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917\u201327.","journal-title":"Lancet Oncol"},{"issue":"22","key":"420_CR2","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","volume":"22","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin Cancer Res. 2016;22(22):5461\u201371.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"420_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591\u20137.","journal-title":"J Clin Oncol"},{"issue":"20","key":"420_CR4","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312\u20138.","journal-title":"J Clin Oncol"},{"issue":"13","key":"420_CR5","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","volume":"14","author":"TE Hutson","year":"2013","unstructured":"Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14(13):1287\u201394.","journal-title":"Lancet Oncol"},{"issue":"18","key":"420_CR6","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","volume":"33","author":"DF McDermott","year":"2015","unstructured":"McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013\u201320.","journal-title":"J Clin Oncol"},{"issue":"19","key":"420_CR7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"8","key":"420_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331.","journal-title":"N Engl J Med"},{"issue":"22","key":"420_CR9","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584\u201390.","journal-title":"J Clin Oncol"},{"issue":"21","key":"420_CR10","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","volume":"295","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516\u201324.","journal-title":"JAMA"},{"issue":"6","key":"420_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"420_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","volume":"49","author":"CN Sternberg","year":"2013","unstructured":"Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287\u201396.","journal-title":"Eur J Cancer"},{"issue":"13","key":"420_CR13","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"420_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/1756287216663979","volume":"8","author":"TA Schmid","year":"2016","unstructured":"Schmid TA, Gore ME. Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2016;8(6):348\u201371.","journal-title":"Ther Adv Urol"},{"issue":"1","key":"420_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1756287215614236","volume":"8","author":"D Cella","year":"2016","unstructured":"Cella D, Beaumont JL. Pazopanib in the treatment of advanced renal cell carcinoma. Ther Adv Urol. 2016;8(1):61\u20139.","journal-title":"Ther Adv Urol"},{"issue":"18","key":"420_CR16","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJMc1400731","volume":"370","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014;370(18):1769\u201370.","journal-title":"N Engl J Med"},{"issue":"6","key":"420_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/01.COT.0000482225.33164.30","volume":"38","author":"E Susman","year":"2016","unstructured":"Susman E. Pazopanib or sunitinib in metastatic renal cancer: Outcomes are similar. Oncology Times. 2016;38(6):17.","journal-title":"Oncology Times"},{"key":"420_CR18","doi-asserted-by":"crossref","unstructured":"Morales JMR, Wells JC, Donskov F, Bjarnason GA, Lee JL, Knox JJ, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). J Clin Oncol. 2016;34(suppl 2S):Abstract 544.","DOI":"10.1200\/jco.2016.34.2_suppl.544"},{"issue":"1","key":"420_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/bjc.2015.196","volume":"113","author":"ME Gore","year":"2015","unstructured":"Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer. 2015;113(1):12\u20139.","journal-title":"Br J Cancer"},{"issue":"2","key":"420_CR20","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.18632\/oncotarget.13895","volume":"8","author":"Y Dong","year":"2017","unstructured":"Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8(2):2171\u201386.","journal-title":"Oncotarget"},{"key":"420_CR21","unstructured":"OPDIVO\u00ae (nivolumab) injection [prescribing information]. Bristol-Myers Squibb: Princeton, NJ; 2018."},{"key":"420_CR22","unstructured":"European Medicines Agency. European public assessment report (EPAR) for Opdivo. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=\/pages\/medicines\/human\/medicines\/003985\/human_med_001876.jsp&mid=WC0b01ac058001d124 . Accessed November 7, 2017."},{"issue":"34","key":"420_CR23","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","volume":"35","author":"HJ Hammers","year":"2017","unstructured":"Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol. 2017;35(34):3851\u20138.","journal-title":"J Clin Oncol"},{"issue":"14","key":"420_CR24","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"6","key":"420_CR25","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148\u201357.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"420_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","volume":"37","author":"PE Hughes","year":"2016","unstructured":"Hughes PE, Caenepeel S, Wu LC. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol. 2016;37(7):462\u201376.","journal-title":"Trends Immunol"},{"issue":"3","key":"420_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","volume":"19","author":"MB Atkins","year":"2018","unstructured":"Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19(3):405\u201315.","journal-title":"Lancet Oncol"},{"key":"420_CR28","doi-asserted-by":"crossref","unstructured":"Lee C, Makker V, Rasco D, Taylor M, Dutcus C, Shumaker R, et al. A phase 1b\/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma. Ann Oncol. 2017;28(suppl 5):Abstract 847O.","DOI":"10.1093\/annonc\/mdx371.002"},{"key":"420_CR29","doi-asserted-by":"crossref","unstructured":"Chowdhury S, McDermott DF, Voss MH, Hawkins RE, Aimone P, Voi M, et al. A phase I\/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2017;35(suppl):Abstract 4506.","DOI":"10.1200\/JCO.2017.35.15_suppl.4506"},{"issue":"6","key":"420_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/1740774510382799","volume":"7","author":"Y Ji","year":"2010","unstructured":"Ji Y, Liu P, Li Y, Bekele BN. A modified toxicity probability interval method for dose-finding trials. Clin Trials. 2010;7(6):653\u201363.","journal-title":"Clin Trials"},{"key":"420_CR31","doi-asserted-by":"crossref","unstructured":"Amin A, Plimack ER, Infante JR, Ernstoff M, Rini BI, McDermott DF, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib (S) or pazopanib (P) in patients (pts) with metastatic renal cell carcinoma (mRCC). Ann Oncol. 2014;25(suppl 4):Abstract 1052PD.","DOI":"10.1093\/annonc\/mdu342.5"},{"issue":"2","key":"420_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.eururo.2015.07.006","volume":"69","author":"C Porta","year":"2016","unstructured":"Porta C, Gore ME, Rini BI, Escudier B, Hariharan S, Charles LP, et al. Long-term safety of sunitinib in metastatic renal cell carcinoma. Eur Urol. 2016;69(2):345\u201351.","journal-title":"Eur Urol"},{"issue":"21","key":"420_CR33","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u201317.","journal-title":"N Engl J Med"},{"issue":"17","key":"420_CR34","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36(17):1668\u201374.","journal-title":"J Clin Oncol"},{"issue":"1","key":"420_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40425-017-0310-x","volume":"6","author":"HL Kaufman","year":"2018","unstructured":"Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after \u22651 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6(1):7.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"420_CR36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/jamaoncol.2017.5440","volume":"4","author":"DP Petrylak","year":"2018","unstructured":"Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, et al. Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 study. JAMA Oncol. 2018;4(4):537\u201344.","journal-title":"JAMA Oncol"},{"issue":"4","key":"420_CR37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","volume":"19","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018;19(4):451\u201360.","journal-title":"Lancet Oncol"},{"key":"420_CR38","doi-asserted-by":"crossref","unstructured":"Atkins MB, McDermott DF, Powles P, Motzer RJ, Rini BI, Fong L, et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol. 2017;35(15 suppl):Abstract 4505.","DOI":"10.1200\/JCO.2017.35.15_suppl.4505"},{"key":"420_CR39","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2018;36(6 suppl):Abstract 578.","DOI":"10.1200\/JCO.2018.36.6_suppl.578"},{"key":"420_CR40","doi-asserted-by":"crossref","unstructured":"Rini BI, Powles T, Chen M, Puhlmann M, Atkins MB. Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced\/metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2017;35(suppl):Abstract TPS4597.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4597"},{"key":"420_CR41","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Rini BI, Larkin JMG, Bjarnason GA, Gravis G, Gurney H, et al. Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101). J Clin Oncol. 2017;35(suppl):Abstract TPS4594.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4594"},{"key":"420_CR42","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Grunwald V, Hutson TE, Porta C, Powles T, Eto M, et al. A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC). J Clin Oncol. 2017;35(suppl):Abstract TPS4595.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4595"},{"key":"420_CR43","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Apolo AB, Powles T, Escudier B, Aren OR, Shah A, et al. A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER). J Clin Oncol. 2018;36(suppl):Abstract TPS4598.","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4598"}],"updated-by":[{"DOI":"10.1186\/s40425-019-0559-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0420-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0420-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0420-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T11:58:07Z","timestamp":1662292687000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0420-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["420"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0420-0","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s40425-019-0559-3","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"assertion":[{"value":"5 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":".","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The CheckMate 016 study was approved by the local site-specific institutional review boards or an independent ethics committee and conducted in accordance with International Conference on Harmonisation Good Clinical Practice guidelines. Written informed consent was obtained from all patients based on Declaration of Helsinki principles before initiation of any study procedures. The trail was registered on(NCT01472081) on November 16, 2011.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The following represents disclosure information provided by authors of this manuscript.<b>AA.<\/b> Honoraria: Bristol-Myers Squibb, Pfizer, Merck, Exelixis. Consulting or Advisory Role: Bristol-Myers Squibb, Merck. Research Funding: Bristol-Myers Squibb, Merck, Dynavax. Travel, Accommodations, Expenses: Bristol-Myers Squibb, Pfizer, Merck, Exelixis. <b>ERP.<\/b> Consulting or Advisory Role: Bristol-Myers Squibb, Acceleron, Astellas, AstraZeneca, Dendreon, Genentech\/Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Eli Lilly Inc., SynerGene Therapeutics, Inovio, Clovis, Horizon Pharma, Exelixis, Aveo Pharmaceuticals (Inst), Bristol-Myers Squibb (Inst), Dendreon (Inst), GlaxoSmithKline (Inst), Eli Lilly Inc. (Inst), Merck (Inst), Peloton (Inst), Pfizer (Inst). Research Funding: Bristol-Myers Squibb, Acceleron (Inst), AstraZeneca (Inst). Patents, Royalties, Other Intellectual Property: U.S. Patent Application No. 14\/588,503, pending, filed 1\/2\/2015; US Patent Application No. 15\/226,474, pending, filed 7\/1\/2015. Travel, Accommodations, Expenses: Bristol-Myers Squibb. Other Relationship: Bristol-Myers Squibb (fees for participating in review activities; for writing or reviewing the manuscript; for providing writing assistance, medicines, equipment, or admin support; development of educational presentations); Merck (fees for development of educational presentations); Roche (fees for development of educational presentations); Novartis (fees for development of educational presentations). <b>MSE.<\/b> Stock ownership (managed account): Bristol-Myers Squibb. <b>LDL.<\/b> No relationship to disclose. <b>TMB.<\/b> Employment: Tennessee Oncology, Sarah Cannon Research Institute. Consulting or Advisory Role: Ignyta (Inst), Guardant Health, Loxo, Pfizer, Moderna Therapeutics (Inst). Research Funding: (Inst) Daiichi Sankyo, Medpacto, Inc., Incyte, Mirati Therapeutics, MedImmune, AbbVie, AstraZeneca, Leap Therapeutics, MabVax, Stemline Therapeutics, Merck, Lilly, GlaxoSmithKline, Novartis, Pfizer, Principa Biopharma, Genentech\/Roche, Deciphera, Merrimack, Immunogen, Millennium, Ignyta, Calithera Biosciences, Kolltan Pharmaceuticals, Peleton, Immunocore, Roche, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Moderna Therapeutics, Sanofi, Boehringer Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio. <b>DFM.<\/b> Consulting or Advisory Role: Array BioPharma, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Merck, Novartis, Pfizer. Research Funding: Prometheus (Inst). <b>MC.<\/b> Consulting or Advisory Role: AstraZeneca, Merck, Astellas, Medivation. <b>CK.<\/b> Honoraria: Bristol-Myers Squibb, Pfizer. Consulting or Advisory Role: Bristol-Myers Squibb, Pfizer. <b>BIR.<\/b> Consulting or Advisory Role: Bristol-Myers Squibb. <b>DYCH.<\/b> Consulting or Advisory Role: Bristol-Myers Squibb, Pfizer, Novartis. <b>JK.<\/b> No relationship to disclose. <b>MHV.<\/b> Honoraria: Novartis. Consulting or Advisory Role: GlaxoSmithKline, Exelixis, Natera, Calithera, Pfizer. Research Funding: Bristol-Myers Squibb, Roche\/Genentech. Travel, Accommodations, Expenses: Takeda, Novartis. <b>JS.<\/b> Honoraria: Celgene, Lilly. Consulting or Advisory Role: Celgene, Lilly. Research Funding: Celgene, Sanofi, Roche. <b>EB.<\/b> Employment: Bristol-Myers Squibb. Stock or Other Ownership: Bristol-Myers Squibb. <b>LY.<\/b> Employment: Bristol-Myers Squibb, at the time the study was performed. Stock or Other Ownership: Bristol-Myers Squibb, at the time the study was performed. <b>HJH.<\/b> Consulting or Advisory Role: Bristol-Myers Squibb, Pfizer, Exelixis. Research Funding: Bristol-Myers Squibb. Travel, Accommodations, Expenses: Bristol-Myers Squibb, Pfizer, Exelixis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"109"}}